Skip to Main Content

Kevan Herold, MD

C.N.H. Long Professor of Immunobiology and of Medicine (Endocrinology)

Research Summary

The work in our laboratory involves translational studies in human immunology, focused on Type 1 diabetes. We are carrying out clinical studies of new immune therapies, in particular humanized anti-CD3 monoclonal antibody, and study the metabolic and immunologic effects of these interventions on the disease process. We showed how treatment with this drug, teplizumab, can delay or prevent the onset of diabetes in relatives who are at risk for disease. We are studying the ability of this intervention to prevent diabetes alone or with other treatments. We have identified a novel regulatory mechanism that we believe is involved in the progression to autoimmune diabetes and plan to expand these studies so that precise therapies can be curtailed to patients.

In addition, we are interested in developing new ways to improve beta cell function and mass which are compromised in all forms of diabetes. We are testing whether immune interventions can lead to spontaneous restoration of beta cell mass and developing new approaches to stimulate beta cell regeneration. Our studies to address this goal involve studies in patients and in animal models of the disease.

We also have an interest in autoimmune diseases that are occur in patients with cancers who are treated with new immune therapies such as checkpoint inhibitors that are given to patients with cancers. We are studying the mechanisms that lead to these adverse events with the objective to prevent them from occurring.



Specialized Terms: Type 1 diabetes; Immune therapy; Autoimmunity

Extensive Research Description

The pathogenesis and treatment of autoimmune disease, in particular Type 1 diabetes.

Studies involve clinical trials with patients and investigations of the mechanism of action of immune therapies and the pathogenesis of disease in patients as well as in animal models when needed to address what cannot be studies in humans. Over the past 7 years, our lab has carried out trials of a humanized non-FcR binding anti-CD3 monoclonal antibody in patients and has studied the mechanism of drug action. These clinical studies have suggested novel mechanisms of immune regulation that are now to be addressed with new clinical studies.

Coauthors

Research Interests

Diabetes Mellitus, Type 1; Endocrine System Diseases; Immune System Diseases; Metabolism; Autoimmunity; Polyendocrinopathies, Autoimmune; Translational Medical Research

Public Health Interests

Immunology; Metabolism

Selected Publications

Clinical Trials

ConditionsStudy Title
Diabetes Mellitus - Type 1TrialNet TOPPLE Study for People with Type 1 Diabetes
Diabetes Mellitus - Type 1Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab (PROTECT)
Diabetes Mellitus - Type 1Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus (TN-22)
Diseases of the Nervous SystemImaging pancreatic beta-cells with PET neuroimaging agent 11C-PHNO
Diabetes Mellitus - Type 1; Diseases of the Endocrine System; Diseases of the Nervous SystemImpact of Hypoglycemia on Brain Ketone and Neurotransmitter Metabolism in Type 1 DM
Children's Health; Diabetes Mellitus - Type 1; Diseases of the Endocrine SystemPathway to Prevention Study
Children's Health; Diabetes Mellitus - Type 1Type 1 Diabetes Extension Study (T1DES)